Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Immuneering Corporation is a clinical-stage oncology company focused on developing and commercializing more effective and better tolerated therapies for cancer patients [3] - The company's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK aimed at improving tolerability and expanding indications to include RAS-driven tumors, such as most pancreatic cancers [3] - IMM-1-104 is currently undergoing a Phase 1/2a trial in patients with advanced solid tumors, including pancreatic cancer [3] - Another product, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of MEK, also in a Phase 1/2a trial for patients with advanced solid tumors harboring RAS or RAF mutations [3] Upcoming Events - Immuneering management will present at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, discussing the company's pipeline, platform, and business strategy [1] - The presentation is scheduled for April 9 from 1:30 – 2:10 pm ET and will be webcast live, with an archive available on the company's Investor Relations website [2]